IS7402A - New crystalline forms of atorvastatin semi-calcium and methods for producing them, as well as new methods for producing atorvastatin semi-calcium forms I, VIII and IX - Google Patents
New crystalline forms of atorvastatin semi-calcium and methods for producing them, as well as new methods for producing atorvastatin semi-calcium forms I, VIII and IXInfo
- Publication number
- IS7402A IS7402A IS7402A IS7402A IS7402A IS 7402 A IS7402 A IS 7402A IS 7402 A IS7402 A IS 7402A IS 7402 A IS7402 A IS 7402A IS 7402 A IS7402 A IS 7402A
- Authority
- IS
- Iceland
- Prior art keywords
- producing
- calcium
- methods
- new
- forms
- Prior art date
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title 2
- 229960005370 atorvastatin Drugs 0.000 title 2
- 229910052791 calcium Inorganic materials 0.000 title 1
- 239000011575 calcium Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35718102P | 2002-02-15 | 2002-02-15 | |
| US42532502P | 2002-11-12 | 2002-11-12 | |
| PCT/US2003/005384 WO2003070702A1 (en) | 2002-02-15 | 2003-02-19 | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS7402A true IS7402A (en) | 2004-08-13 |
Family
ID=27760457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS7402A IS7402A (en) | 2002-02-15 | 2004-08-13 | New crystalline forms of atorvastatin semi-calcium and methods for producing them, as well as new methods for producing atorvastatin semi-calcium forms I, VIII and IX |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1480950A4 (en) |
| JP (2) | JP2005519076A (en) |
| KR (1) | KR100724515B1 (en) |
| CN (1) | CN100406436C (en) |
| AU (1) | AU2003217653A1 (en) |
| CA (1) | CA2475864A1 (en) |
| DE (1) | DE03713610T1 (en) |
| ES (1) | ES2241507T1 (en) |
| HR (1) | HRP20040768A2 (en) |
| IS (1) | IS7402A (en) |
| MX (1) | MXPA04007939A (en) |
| NO (1) | NO20043842L (en) |
| PL (1) | PL372303A1 (en) |
| WO (1) | WO2003070702A1 (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| KR20090045420A (en) | 2002-02-19 | 2009-05-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | Desolvation of atorvastatin hemi-calcium solvates |
| EP1572643A2 (en) * | 2002-11-28 | 2005-09-14 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| CA2672554C (en) | 2004-07-20 | 2012-01-03 | Warner-Lambert Company Llc | Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| EP1711464A2 (en) * | 2004-07-22 | 2006-10-18 | Teva Pharmaceutical Industries Ltd | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation |
| WO2006048894A1 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | Novel crystalline forms of atorvastatin calcium and processes for preparing them. |
| JP5523699B2 (en) * | 2005-04-08 | 2014-06-18 | エギシュ ヂョヂセルヂャール ニルヴァーノサン ミケデ レースヴェーニタールササーグ | A new crystalline polymorph of atorvastatin hemi-calcium salt |
| DK1957452T3 (en) | 2005-11-21 | 2010-07-26 | Warner Lambert Co | Novel forms of [R- (R *, R *)] - 2- (4-fluorophenyl) -B, B-dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] - 1H-pyrrole-1-heptanoic acid magnesium |
| CA2633268A1 (en) | 2005-12-13 | 2007-06-21 | Teva Pharmaceutical Industries Ltd. | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
| US20070265456A1 (en) * | 2006-05-09 | 2007-11-15 | Judith Aronhime | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| US7915302B2 (en) | 2007-03-02 | 2011-03-29 | Dong-A Pharm. Co., Ltd. | Crystal forms of pyrrolylheptanoic acid derivatives |
| KR20120011249A (en) * | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | Novel crystalline forms of atorvastatin hemicalcium salts, hydrates thereof, and methods for preparing the same |
| KR101324862B1 (en) * | 2011-07-12 | 2013-11-01 | (주)에이에스텍 | Spherical particle of clopidogrel bisulfate, pharmaceutical composition comprising the same and method of preparation thereof |
| KR102495018B1 (en) | 2013-11-15 | 2023-02-06 | 아케비아 테라퓨틱스 인코포레이티드 | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
| CN105055357A (en) * | 2015-09-25 | 2015-11-18 | 青岛华之草医药科技有限公司 | Atorvastatin calcium composition tablet for treating hypercholesteremia |
| KR101723783B1 (en) * | 2017-02-24 | 2017-04-07 | 주식회사 경보제약 | Novel Crystal Form of Atorvastatin Hemi-Calcium, Hydrate thereof, and Method of Producing the Same |
| WO2025147589A1 (en) | 2024-01-05 | 2025-07-10 | Osanni Bio, Inc. | Implants, compositions, and methods for treating retinal diseases and disorders |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1148049T1 (en) * | 1995-07-17 | 2005-02-28 | Warner-Lambert Company | Crystalline R-(R*,R*)$-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl -1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
| HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
| DE60018100T2 (en) * | 1999-11-17 | 2005-09-15 | Teva Pharmaceutical Industries Ltd. | POLYMORPHIC FORM OF ATORVASTATIN CALCIUM |
| CA2391357C (en) * | 1999-12-17 | 2009-01-06 | Warner Lambert Research And Development Ireland Limited | A process for producing crystalline atorvastatin calcium |
| ES2252088T3 (en) * | 1999-12-17 | 2006-05-16 | Pfizer Science And Technology Ireland Limited | PROCEDURE OF INDUSTRIAL SCALE PRODUCTION OF THE CALCIUM HEMISAL OF ATORVASTATIN CRYSTAL HYDROCHLATE. |
| IL155734A0 (en) * | 2000-11-03 | 2003-11-23 | Teve Pharmaceutical Ind Ltd | Atorvastatin hemi-calcium form vii |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| ES2319870T3 (en) * | 2000-12-27 | 2009-05-14 | Teva Pharmaceutical Industries Limited | CRYSTALLINE FORMS OF ATORVASTATIN. |
| WO2002057229A1 (en) * | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| HUP0400381A2 (en) * | 2001-06-29 | 2004-09-28 | Warner-Lambert Company Llc | Crystalline forms of r-(r*,r*)-2-(4-fluorphenyl)-betha, delta dihydroxy-5-(1-methylethyl)-3-phenyl-4-phenylaminocarbonyl-iii-pyrrole-1-heptanoic acid calcium salt (2:1)(atorvastatin) |
| EE200400048A (en) * | 2001-07-30 | 2004-04-15 | Dr. Reddy's Laboratories Ltd. | Crystalline Forms VI and VII of Atorvastatin Calcium |
| UA77990C2 (en) * | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
| AU2002330735A1 (en) * | 2002-09-03 | 2004-03-29 | Morepen Laboratories Limited | Atorvastatin calcium form vi or hydrates thereof |
| EP1572643A2 (en) * | 2002-11-28 | 2005-09-14 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
-
2003
- 2003-02-19 AU AU2003217653A patent/AU2003217653A1/en not_active Abandoned
- 2003-02-19 JP JP2003569609A patent/JP2005519076A/en not_active Withdrawn
- 2003-02-19 ES ES03713610T patent/ES2241507T1/en active Pending
- 2003-02-19 KR KR1020047012591A patent/KR100724515B1/en not_active Expired - Fee Related
- 2003-02-19 DE DE03713610T patent/DE03713610T1/en active Pending
- 2003-02-19 EP EP03713610A patent/EP1480950A4/en not_active Withdrawn
- 2003-02-19 MX MXPA04007939A patent/MXPA04007939A/en unknown
- 2003-02-19 WO PCT/US2003/005384 patent/WO2003070702A1/en not_active Ceased
- 2003-02-19 HR HR20040768A patent/HRP20040768A2/en not_active Application Discontinuation
- 2003-02-19 CN CNB038082071A patent/CN100406436C/en not_active Expired - Fee Related
- 2003-02-19 PL PL03372303A patent/PL372303A1/en not_active Application Discontinuation
- 2003-02-19 CA CA002475864A patent/CA2475864A1/en not_active Abandoned
-
2004
- 2004-08-13 IS IS7402A patent/IS7402A/en unknown
- 2004-09-14 NO NO20043842A patent/NO20043842L/en not_active Application Discontinuation
-
2009
- 2009-06-08 JP JP2009137400A patent/JP2009235083A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003070702A1 (en) | 2003-08-28 |
| AU2003217653A1 (en) | 2003-09-09 |
| ES2241507T1 (en) | 2005-11-01 |
| KR20040081202A (en) | 2004-09-20 |
| PL372303A1 (en) | 2005-07-11 |
| EP1480950A1 (en) | 2004-12-01 |
| KR100724515B1 (en) | 2007-06-04 |
| HRP20040768A2 (en) | 2005-06-30 |
| EP1480950A4 (en) | 2005-05-18 |
| CA2475864A1 (en) | 2003-08-28 |
| CN1646490A (en) | 2005-07-27 |
| JP2009235083A (en) | 2009-10-15 |
| NO20043842L (en) | 2004-09-14 |
| DE03713610T1 (en) | 2005-10-20 |
| CN100406436C (en) | 2008-07-30 |
| MXPA04007939A (en) | 2004-11-26 |
| JP2005519076A (en) | 2005-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS7402A (en) | New crystalline forms of atorvastatin semi-calcium and methods for producing them, as well as new methods for producing atorvastatin semi-calcium forms I, VIII and IX | |
| FI20030241L (en) | Method for producing synthesis gas | |
| CY2015015I1 (en) | PRODUCTION OF THIACOMYCIN | |
| IS7261A (en) | N-adamantylmethyl derivatives and intermediates as pharmaceutical compositions and methods for producing them | |
| FI20022084L (en) | Method of making newsprint | |
| DK1654438T3 (en) | Process for natural gas production | |
| PL2415577T3 (en) | Methods of producing gel sheets | |
| IS7600A (en) | A method of promoting smoke | |
| DK1518827T3 (en) | Crystallized IM-12 solid and process for its preparation | |
| IS2979B (en) | Process for producing N-substituted 2-cyanopyrrolidine | |
| IS8035A (en) | New photostable stable groups for improved methods of producing oligomeric arrays | |
| AU2003261191A8 (en) | Methods for producing biopolymers | |
| PL394821A1 (en) | Production method of combrestinates | |
| IS8416A (en) | Method of production of CCR-2 antagonist | |
| IS7069A (en) | Method of producing zaleplon | |
| DK1890570T3 (en) | Toothbrush head and method of manufacture thereof | |
| IS7981A (en) | Method for producing microsystems | |
| FI20031467L (en) | Method and arrangement for producing experiences | |
| EP1600511A4 (en) | Method of treating ischemic disease | |
| NO20043568D0 (en) | Method of Preparing Citalopram | |
| EP1592431A4 (en) | Method of modulating il-6 | |
| FI20031639A7 (en) | Method for producing somatic embryos of conifers | |
| FI20010892L (en) | Method for producing xylitol | |
| ITMI20021432A0 (en) | METHOD FOR PRODUCING CEPHALOSPORINS | |
| IS6928A (en) | Methods for producing mirtasapine intermediates |